Diabetic Foot Clinical Trial
Official title:
A Randomized, Open Label, Controlled, Phase 2, Multi-Center Study to Assess Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 (Pravibismane Topical Suspension) in Subjects With Moderate Diabetic Foot Infection (DFI)
Verified date | February 2024 |
Source | Microbion Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.
Status | Active, not recruiting |
Enrollment | 54 |
Est. completion date | March 2024 |
Est. primary completion date | January 19, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion Criteria: - Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria. - Has a skin ulcer located on or distal to the malleolus that is = 4 weeks that is clinically documented, and presents with clinical manifestations of a moderate infection (i.e. erythema extending = 2.0 cm from the wound margin), and not requiring hospitalization. - Has received no more than 36 hours of antibiotic therapy for the moderately infected ulcer prior to enrollment or there is clinical and/or microbiological evidence of failure of antibiotic treatment for the treatment of the moderately infected ulcer. - Has documented adequate arterial perfusion in the affected limb by biphasic or triphasic Doppler wave forms, a toe brachial index (TBI) =0.75, or an ankle brachial index (ABI) of >0.9). - Has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained. Exclusion Criteria: - Has proven or highly suspected, involvement of bone (i.e., osteomyelitis). - Has an ulcer due to Charcot arthropathy. - Has more than one concurrent, infected, diabetic foot wound on the study limb. - Is unwilling or unable to attend clinic visits and keep research appointments. - Is unwilling or unable to adhere to the systemic antibiotic treatment prescribed. - Is unwilling or unable to adhere to proper pressure off-loading of the foot wound (when needed) from enrollment through EOS as directed by the treating physician. - Has an untreated, uncontrolled, or poorly managed immunosuppressive and or autoimmune disorder. - Plans to use any topical antibiotics, herbals remedies (e.g., honey), alternative medicines or antimicrobials, either directly or by dressings on their infected DFU at any time from enrollment through the EOS visit. - Plans to receive treatment with larvae (maggots) for their infected DFU at any time from enrollment through the EOS visit. - Plans to receive treatment with advanced cellular therapies (e.g., Platelet-derived growth factor (PDGF), Cellular Tissue Products (CTP), granulocyte colony-stimulating factor (G CSF)) for their infected DFU at any time from enrollment through the EOS visit. - History of major medical noncompliance. - Any condition that has required treatment with any other bismuth containing compound within 2 weeks prior to enrollment through EOS visit (i.e., Kaopectate or Pepto-Bismol, including topical applications such as Xeroform). - Plans to receive treatment with Hyperbaric oxygen therapy (HBOT) or topical negative pressure wound therapy (NPWT) for their infected DFU at any time from enrollment through the EOS visit. - Glycated hemoglobin >12%. - Has a serum creatinine, ALT, AST or Alkaline Phosphatase >3 times the upper limit of the normal range of the local testing laboratory. - End stage renal disease requiring dialysis. - Has an absolute neutrophil count <1000. - Has participated in an investigational trial to evaluate pharmaceuticals or biologics either concurrently or within the past 30 days. - Will undergo a planned surgical therapy beyond standard bedside debridement or incision and drainage, to treat the DFI after enrollment. - Has a known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80)). - Is immunocompromised and not well-managed due to illness [human immunodeficiency virus (HIV), autoimmune disease] or organ transplant. - Has a history of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix) unless the subject has been free of cancer for > 5 years. - Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures. - Active alcohol abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroin, or methamphetamines) or if drug or alcohol use will interfere with visits in clinic in the opinion of the investigator. - Has other medical condition(s) which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results. |
Country | Name | City | State |
---|---|---|---|
United States | Parkland Comprehensive Wound Center | Dallas | Texas |
United States | Parkland Memorial Hospital | Dallas | Texas |
United States | University of Texas Southwestern Medical Center University Wound Care Clinic | Dallas | Texas |
United States | University of Texas Southwestern Medical Center William P. Clements Jr. University Hospital | Dallas | Texas |
United States | Limb Preservation Platform, Inc. | Fresno | California |
United States | Futuro Clinical Trials, LLC | McAllen | Texas |
United States | Bio-X-Cell Research | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Microbion Corporation | CUBRC, MTEC, and US Navy |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with adverse events | Safety and tolerability | 12 weeks | |
Secondary | Proportion of subjects with complete wound closure | Effect of MBN-101 suspension on wound healing | 12 weeks | |
Secondary | Proportion of subjects with a clinical cure of infection | Effect of MBN-101 suspension on resolution of infection | 12 weeks | |
Secondary | Proportion of subjects undergoing lower-extremity amputation | Effect of topical pravibismane (MBN-101) suspension on the incidence of lower level extremity amputations | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06154915 -
Immune Cells in Diabetic Chronic Foot Ulcers
|
||
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02373592 -
Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer
|
N/A | |
Active, not recruiting |
NCT01903044 -
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
|
Phase 1/Phase 2 | |
Completed |
NCT02092870 -
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
|
Phase 2 | |
Completed |
NCT01212120 -
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections
|
N/A | |
Completed |
NCT00402727 -
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
|
Phase 3 | |
Recruiting |
NCT04085705 -
The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
|
||
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Completed |
NCT04480801 -
The Effect of Thermal Evaluation in Prevention of Diabetic Foot Ulcer
|
N/A | |
Not yet recruiting |
NCT04537676 -
Patient Empowerment Study
|
||
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A | |
Recruiting |
NCT05974592 -
The Effect of Nurse-Led Diabetic Foot Self-Management Training Program
|
N/A | |
Not yet recruiting |
NCT04630795 -
ViscoTurf - Preventing Secondary Diabetic Foot Ulceration.
|
||
Not yet recruiting |
NCT05431660 -
Diabetic Foot School and Biomechanics
|
N/A | |
Completed |
NCT05101473 -
Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study
|
N/A | |
Completed |
NCT05123157 -
Pattern and Type of Amputation and Mortality Rate Associated With Diabetic Foot in Jeddah, Saudi Arabia: A Retrospective Cohort Study
|
||
Enrolling by invitation |
NCT05043636 -
Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
|
||
Completed |
NCT03254095 -
Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.
|